4.4 Review

Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment

期刊

MEDICAL ONCOLOGY
卷 40, 期 12, 页码 -

出版社

HUMANA PRESS INC
DOI: 10.1007/s12032-023-02195-3

关键词

Nanomedicine; Oncoproteins; Pathophysiology; Angiogenesis; Cervical cancer; Immunotherapy; Tumor suppressor genes

类别

向作者/读者索取更多资源

Nanomedicine offers new possibilities for the treatment of cervical cancer, with tailored delivery systems, precise targeting, combination therapies, real-time monitoring, and diverse nanocarriers. These systems allow for targeted delivery of therapeutic drugs to cancer cells, minimizing negative effects on healthy tissues. Surface modification of nanocarriers and co-delivery of multiple drugs also enhance treatment options. Combination therapies involving chemotherapy, gene therapy, immunotherapy, and photodynamic therapy have shown promising results in preclinical and clinical studies.
Cervical cancer is a huge worldwide health burden, impacting women in impoverished nations in particular. Traditional therapeutic approaches, such as surgery, radiation therapy, and chemotherapy, frequently result in systemic toxicity and ineffectiveness. Nanomedicine has emerged as a viable strategy for targeted delivery of therapeutic drugs to cancer cells while decreasing off-target effects and increasing treatment success in recent years. Nanomedicine for cervical cancer introduces several novel aspects that distinguish it from previous treatment options such as tailored delivery system, precision targeting, combination therapies, real-time monitoring and diverse nanocarriers to overcome the limitations of one another. This abstract presents recent advances in nanomedicine-based tailored delivery systems for the treatment of cervical cancer. Liposomes, polymeric nanoparticles, dendrimers, and carbon nanotubes have all been intensively studied for their ability to transport chemotherapeutic medicines, nucleic acids, and imaging agents to cervical cancer cells. Because of the way these nanocarriers are designed, they may cross biological barriers and preferentially aggregate at the tumor site, boosting medicine concentration and lowering negative effects on healthy tissues. Surface modification of nanocarriers with targeting ligands like antibodies, peptides, or aptamers improves specificity for cancer cells by identifying overexpressed receptors or antigens on the tumor surface. Furthermore, nanomedicine-based techniques have made it possible to co-deliver numerous therapeutic drugs, allowing for synergistic effects and overcoming drug resistance. In preclinical and clinical investigations, combination treatments comprising chemotherapeutic medicines, gene therapy, immunotherapy, and photodynamic therapy have showed encouraging results, opening up new avenues for individualized and multimodal treatment regimens. Furthermore, the inclusion of contrast agents and imaging probes into nanocarrier systems has enabled real-time monitoring and imaging of treatment response. This enables the assessment of therapy efficacy, the early diagnosis of recurrence, and the optimization of treatment regimens.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据